{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T12:30:47Z","timestamp":1793881847814,"version":"4.7.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T00:00:00Z","timestamp":1689033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T00:00:00Z","timestamp":1689033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s13555-023-00974-4","type":"journal-article","created":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T09:01:36Z","timestamp":1689066096000},"page":"1721-1731","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Use of 5-Alpha Reductase Inhibitors in Dermatology: A Narrative Review"],"prefix":"10.1007","volume":"13","author":[{"given":"Mariana","family":"Escamilla-Cruz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Maga\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Escand\u00f3n-Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3093-937X","authenticated-orcid":false,"given":"Omar Yaxmehen","family":"Bello-Chavolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,11]]},"reference":[{"issue":"3","key":"974_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s11154-015-9319-y","volume":"16","author":"AM Traish","year":"2015","unstructured":"Traish AM, Melcangi RC, Bortolato M, Garcia-Segura LM, Zitzmann M. Adverse effects of 5\u03b1-reductase inhibitors: what do we know, don\u2019t know, and need to know? Rev Endocr Metab Disord. 2015;16(3):177\u201398.","journal-title":"Rev Endocr Metab Disord"},{"issue":"2","key":"974_CR2","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJM199401133300208","volume":"330","author":"AJJ Wood","year":"1994","unstructured":"Wood AJJ, Rittmaster RS. Finasteride. N Engl J Med. 1994;330(2):120\u20135.","journal-title":"N Engl J Med"},{"issue":"6","key":"974_CR3","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jaad.2006.05.007","volume":"55","author":"EA Olsen","year":"2006","unstructured":"Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 2006;55(6):1014\u201323.","journal-title":"J Am Acad Dermatol"},{"issue":"8\u20139","key":"974_CR4","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/S0531-5565(02)00093-1","volume":"37","author":"RM Tr\u00fceb","year":"2002","unstructured":"Tr\u00fceb RM. Molecular mechanisms of androgenetic alopecia. Exp Gerontol. 2002;37(8\u20139):981\u201390.","journal-title":"Exp Gerontol"},{"issue":"4","key":"974_CR5","first-page":"550","volume":"41","author":"L Drake","year":"1999","unstructured":"Drake L, Hordinsky M, Fiedler V, et al. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. J Am Acad Dermatol. 1999;41(4):550\u20134.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"974_CR6","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1046\/j.1365-2133.2000.03780.x","volume":"143","author":"D Van Neste","year":"2000","unstructured":"Van Neste D, Fuh V, Sanchez-Pedreno P, et al. Finasteride increases anagen hair in men with androgenetic alopecia. Br J Dermatol. 2000;143(4):804\u201310.","journal-title":"Br J Dermatol"},{"issue":"1","key":"974_CR7","first-page":"38","volume":"12","author":"Finasteride Male Pattern Hair Loss Study Group","year":"2002","unstructured":"Finasteride Male Pattern Hair Loss Study Group. Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia. Eur J Dermatol. 2002;12(1):38\u201349.","journal-title":"Eur J Dermatol"},{"issue":"2","key":"974_CR8","first-page":"150","volume":"13","author":"DA Whiting","year":"2003","unstructured":"Whiting DA, Olsen EA, Savin R, et al. Efficacy and tolerability of finasteride 1 mg in men aged 41\u201360 years with male pattern hair loss. Eur J Dermatol. 2003;13(2):150\u201360.","journal-title":"Eur J Dermatol"},{"issue":"4","key":"974_CR9","first-page":"247","volume":"14","author":"M Kawashima","year":"2004","unstructured":"Kawashima M, Hayashi N, Igarashi A, et al. Finasteride in the treatment of Japanese men with male pattern hair loss. Eur J Dermatol. 2004;14(4):247\u201354.","journal-title":"Eur J Dermatol"},{"issue":"10","key":"974_CR10","doi-asserted-by":"publisher","first-page":"842","DOI":"10.5414\/CP202119","volume":"52","author":"M Caserini","year":"2014","unstructured":"Caserini M, Radicioni M, Leuratti C, et al. A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers. Int J Clin Pharmacol Ther. 2014;52(10):842\u20139.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"974_CR11","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/jdv.17738","volume":"36","author":"BM Piraccini","year":"2021","unstructured":"Piraccini BM, Blume-Peytavi U, Scarci F, et al. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. J Eur Acad Dermatol Venereol. 2021;36:286\u201394.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"974_CR12","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1111\/jdv.15171","volume":"32","author":"P Suchonwanit","year":"2018","unstructured":"Suchonwanit P, Srisuwanwattana P, Chalermroj N, Khunkhet S. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs 3% minoxidil solution in the treatment of male androgenetic alopecia. J Eur Acad Dermatol Venereol. 2018;32(12):2257\u201363.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"974_CR13","first-page":"1","volume":"33","author":"P Suchonwanit","year":"2020","unstructured":"Suchonwanit P, Iamsumang W, Leerunyakul K. Topical finasteride for the treatment of male androgenetic alopecia and female pattern hair loss: a review of the current literature. J Dermatol Treat. 2020;33:1\u20136.","journal-title":"J Dermatol Treat"},{"issue":"5 Pt 1","key":"974_CR14","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1067\/mjd.2000.107953","volume":"43","author":"VH Price","year":"2000","unstructured":"Price VH, Roberts JL, Hordinsky M, et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol. 2000;43(5 Pt 1):768\u201376.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"974_CR15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4103\/0974-7753.114709","volume":"5","author":"R Oliveira-Soares","year":"2013","unstructured":"Oliveira-Soares R, Silva EJM, Correia MP, Andr\u00e9 MC. Finasteride 5 mg\/day treatment of patterned hair loss in normo-androgenetic postmenopausal women. Int J Trichol. 2013;5(1):22\u20135.","journal-title":"Int J Trichol"},{"issue":"5","key":"974_CR16","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1067\/mjd.2002.124608","volume":"47","author":"KW Shum","year":"2002","unstructured":"Shum KW, Cullen DR, Messenger AG. Hair loss in women with hyperandrogenism: four cases responding to finasteride. J Am Acad Dermatol. 2002;47(5):733\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"974_CR17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0015-0282(02)04551-X","volume":"79","author":"E Carmina","year":"2003","unstructured":"Carmina E, Lobo RA. Treatment of hyperandrogenic alopecia in women. Fertil Steril. 2003;79(1):91\u20135.","journal-title":"Fertil Steril"},{"issue":"6","key":"974_CR18","doi-asserted-by":"publisher","first-page":"521","DOI":"10.4103\/0378-6323.144162","volume":"80","author":"IH Boersma","year":"2014","unstructured":"Boersma IH, Oranje AP, Grimalt R, Iorizzo M, Piraccini BM, Verdonschot EH. The effectiveness of finasteride and dutasteride used for 3 years in women with androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2014;80(6):521\u20135.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"1","key":"974_CR19","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40257-018-0387-0","volume":"20","author":"P Suchonwanit","year":"2019","unstructured":"Suchonwanit P, Iamsumang W, Rojhirunsakool S. Efficacy of topical combination of 0.25% finasteride and 3% minoxidil versus 3% minoxidil solution in female pattern hair loss: a randomized, double-blind, controlled study. Am J Clin Dermatol. 2019;20(1):147\u201353.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"974_CR20","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.jaad.2003.07.021","volume":"50","author":"J Leyden","year":"2004","unstructured":"Leyden J, Bergfeld W, Drake L, et al. A systemic type I 5 alpha-reductase inhibitor is ineffective in the treatment of acne vulgaris. J Am Acad Dermatol. 2004;50(3):443\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"974_CR21","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1080\/09513590701214463","volume":"23","author":"C Kohler","year":"2007","unstructured":"Kohler C, Tschumi K, Bodmer C, Schneiter M, Birkhaeuser M. Effect of finasteride 5 mg (Proscar) on acne and alopecia in female patients with normal serum levels of free testosterone. Gynecol Endocrino. 2007;23(3):142\u20135.","journal-title":"Gynecol Endocrino"},{"issue":"4","key":"974_CR22","doi-asserted-by":"crossref","first-page":"237","DOI":"10.4103\/ds.ds_11_19","volume":"37","author":"T Ito","year":"2019","unstructured":"Ito T, Kito Y, Masuda Y, Kageyama R, Tokura Y. Dual effects of 5\u03b1-reductase inhibitor dutasteride on androgenetic alopecia and acne vulgaris. Dermatol Sin. 2019;37(4):237.","journal-title":"Dermatol Sin"},{"issue":"11","key":"974_CR23","doi-asserted-by":"publisher","first-page":"3580","DOI":"10.1111\/jocd.14462","volume":"20","author":"GR Rokni","year":"2021","unstructured":"Rokni GR, Mohammadnezhad F, Saeedi M, et al. Efficacy, tolerability, and safety of montelukast versus finasteride for the treatment of moderate acne in women: a prospective, randomized, single-blinded, active-controlled trial. J Cosmet Dermatol. 2021;20(11):3580\u20135.","journal-title":"J Cosmet Dermatol"},{"issue":"6","key":"974_CR24","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/j.jaad.2018.08.061","volume":"80","author":"S Azarchi","year":"2019","unstructured":"Azarchi S, Bienenfeld A, Lo Sicco K, Marchbein S, Shapiro J, Nagler AR. Androgens in women: hormone-modulating therapies for skin disease. J Am Acad Dermatol. 2019;80(6):1509\u201321.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"974_CR25","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.jaad.2013.12.003","volume":"70","author":"S Va\u00f1\u00f3-Galv\u00e1n","year":"2014","unstructured":"Va\u00f1\u00f3-Galv\u00e1n S, Molina-Ruiz AM, Serrano-Falc\u00f3n C, et al. Frontal fibrosing alopecia: a multicenter review of 355 patients. J Am Acad Dermatol. 2014;70(4):670\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"974_CR26","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1111\/jdv.14930","volume":"32","author":"A Murad","year":"2018","unstructured":"Murad A, Bergfeld W. 5-alpha-reductase inhibitor treatment for frontal fibrosing alopecia: an evidence-based treatment update. J Eur Acad Dermatol Venereol. 2018;32(8):1385\u201390.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"974_CR27","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/j.jaad.2020.09.093","volume":"84","author":"C Pindado-Ortega","year":"2021","unstructured":"Pindado-Ortega C, Saceda-Corralo D, Moreno-Arrones \u00d3M, et al. Effectiveness of dutasteride in a large series of patients with frontal fibrosing alopecia in real clinical practice. J Am Acad Dermatol. 2021;84(5):1285\u201394.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"974_CR28","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1210\/jc.2018-00241","volume":"103","author":"KA Martin","year":"2018","unstructured":"Martin KA, Anderson RR, Chang RJ, et al. Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(4):1233\u201357.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"974_CR29","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1530\/eje.0.1470467","volume":"147","author":"F Bayram","year":"2002","unstructured":"Bayram F, M\u00fcderris II, G\u00fcven M, Kele\u015ftimur F. Comparison of high-dose finasteride (5 mg\/day) versus low-dose finasteride (2.5 mg\/day) in the treatment of hirsutism. Eur J Endocrinol. 2002;147(4):467\u201371.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"974_CR30","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1210\/jc.2017-02052","volume":"103","author":"P Barrionuevo","year":"2018","unstructured":"Barrionuevo P, Nabhan M, Altayar O, et al. Treatment options for hirsutism: a systematic review and network meta-analysis. J Clin Endocrinol Metab. 2018;103(4):1258\u201364.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"974_CR31","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.fertnstert.2019.11.030","volume":"113","author":"AM Traish","year":"2020","unstructured":"Traish AM. Post-finasteride syndrome: a surmountable challenge for clinicians. Fertil Steril. 2020;113(1):21\u201350.","journal-title":"Fertil Steril"},{"issue":"3","key":"974_CR32","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s11930-018-0161-6","volume":"10","author":"AM Traish","year":"2018","unstructured":"Traish AM. The post-finasteride syndrome: clinical manifestation of drug-induced epigenetics due to endocrine disruption. Curr Sex Health Rep. 2018;10(3):88\u2013103.","journal-title":"Curr Sex Health Rep"},{"issue":"50","key":"974_CR33","doi-asserted-by":"publisher","first-page":"82074","DOI":"10.18632\/oncotarget.12617","volume":"7","author":"M Wu","year":"2016","unstructured":"Wu M, Yu Q, Li Q. Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases. Oncotarget. 2016;7(50):82074\u201384.","journal-title":"Oncotarget"},{"key":"974_CR34","unstructured":"PROPECIA\u00ae (finasteride) tablets for oral use. US Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020788s020s021s023lbl.pdf. Accessed 5 June 2023"},{"issue":"3","key":"974_CR35","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1056\/NEJMoa030660","volume":"349","author":"IM Thompson","year":"2003","unstructured":"Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215\u201324.","journal-title":"N Engl J Med"},{"issue":"2","key":"974_CR36","doi-asserted-by":"publisher","first-page":"128","DOI":"10.4103\/0378-6323.177432","volume":"82","author":"V Mysore","year":"2016","unstructured":"Mysore V, Shashikumar BM. Guidelines on the use of finasteride in androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2016;82(2):128\u201334.","journal-title":"Indian J Dermatol Venereol Leprol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-00974-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-023-00974-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-00974-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T17:11:23Z","timestamp":1702746683000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-023-00974-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,11]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["974"],"URL":"https:\/\/doi.org\/10.1007\/s13555-023-00974-4","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,11]]},"assertion":[{"value":"5 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}